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on the locoregional management of locally advanced disease. For up-to-date approaches to metastatic disease, we asked Canadian experts with a special interest in the treatment of her2-positive and her2-negative disease to provide summaries based on already-published international guidelines, but with a Canadian flavour. Lastly, a review of pregnancyrelated breast cancer-that is, breast cancer during pregnancy, or pregnancy after breast cancer-was included as a topic of special interest for practitioners managing the many young women presenting in such circumstances.
Many thanks go to all the contributing oncologists for their work on this special edition and also to Glenn Fletcher, guideline methodologist for the Program in Evidence-Based Care at Cancer Care Ontario. We all hope that this supplement will be an important tool for practising breast cancer oncologists.
Correspondence to: Maureen E. Trudeau, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5. E-mail: maureen.trudeau@sunnybrook.ca I was delighted to be asked to act as guest editor of this Current Oncology supplement dedicated to breast cancer; it was the opportune time to publish the adjuvant breast cancer guidelines recently completed for Cancer Care Ontario's Program in EvidenceBased Care. Finding, in any one place, guidelines and consensus documents that are up to date and evidence-based can be challenging, especially given that the data on breast cancer treatments are constantly changing as new evidence accumulates. In fact, information from the soft and text trials was added just before publication of this supplement because the evidence had not been reported when the guideline recommendations were initially being developed.
Evidence-based reviews or consensus recommendations on both the locoregional management and systemic treatment of locally advanced breast cancer were also sought for the supplement. Over the last few years, a Canadian group of content experts has been working on appropriate algorithms for neoadjuvant treatment. Their just-completed set of recommendations is included here, as is another just-completed set of Cancer Care Ontario guidelines Curr Oncol, Vol. 22, p. S7; doi: http://dx.doi.org/10.3747/co.22.2617 Publication of this supplement was made possible through unrestricted grants from Hoffmann-La Roche, Eisai, AstraZeneca, and Novartis Pharmaceuticals Canada. We sincerely thank them for having accepted to help support this project and for their commitment to research and education in breast cancer.
